This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (53)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John Barton, MD; Robert M. Lavker, PhD; Norman M. Schechter, PhD; Gerald S. Lazarus, MD

Arch Dermatol. 1985;121(12):1516-1523.

Abstract
• Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95% in one patient 48 weeks after injection. In six patients, the topical application of 0.05% betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.

(Arch Dermatol 1985;121:1516-1523)

Author Affiliations
From the Department of Dermatology, University of Pennsylvania, Philadelphia.

Footnotes
Accepted for publication Sept 10, 1985.

Read before the annual meeting of the Society for Investigative Dermatology, Washington, DC, May 5, 1985.

Reprint requests to Department of Dermatology, University of Pennsylvania, 229 Medical Education Bldg, 36th Street and Hamilton Walk, Philadelphia, PA 19104 (Dr Lazarus).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How we diagnose and treat WHO-defined systemic mastocytosis in adults
Tefferi et al.
haematol 2008;93:6-9.
FULL TEXT  

Solitary Mastocytoma Producing Symptoms Mimicking Those of a Seizure Disorder
Krowchuk et al.
J Child Neurol 1994;9:451-453.
 

Intravenous Corticosteroids for Systemic Mastocytosis
Blauvelt and Kerdel
Arch Dermatol 1991;127:1586-1586.
ABSTRACT  

Urticaria Pigmentosa: Systemic Evaluation and Successful Treatment With Topical Steroids
Guzzo et al.
Arch Dermatol 1991;127:191-196.
ABSTRACT  

Wheals and Erythematous Papules in a Generalized Distribution
Lo et al.
Arch Dermatol 1989;125:1415-1416.
ABSTRACT  

Reddish-Brown Macules With Telangiectasia and Pruritus
Parks and Camisa
Arch Dermatol 1988;124:431-432.
ABSTRACT